NO992369D0 - Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus - Google Patents

Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus

Info

Publication number
NO992369D0
NO992369D0 NO992369A NO992369A NO992369D0 NO 992369 D0 NO992369 D0 NO 992369D0 NO 992369 A NO992369 A NO 992369A NO 992369 A NO992369 A NO 992369A NO 992369 D0 NO992369 D0 NO 992369D0
Authority
NO
Norway
Prior art keywords
fiv
recombinants
sub
dna
challenge
Prior art date
Application number
NO992369A
Other languages
English (en)
Other versions
NO992369L (no
Inventor
James Tartaglia
Enzo Paoletti
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25001826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO992369(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of NO992369D0 publication Critical patent/NO992369D0/no
Publication of NO992369L publication Critical patent/NO992369L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO992369A 1996-11-14 1999-05-14 Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus NO992369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/746,668 US7255862B1 (en) 1996-11-14 1996-11-14 ALVAC/FIV constructs
PCT/US1997/020430 WO1998021354A1 (en) 1996-11-14 1997-11-07 Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses

Publications (2)

Publication Number Publication Date
NO992369D0 true NO992369D0 (no) 1999-05-14
NO992369L NO992369L (no) 1999-07-06

Family

ID=25001826

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992369A NO992369L (no) 1996-11-14 1999-05-14 Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus

Country Status (12)

Country Link
US (1) US7255862B1 (no)
EP (1) EP0956360B1 (no)
JP (3) JP4064466B2 (no)
AT (1) ATE330023T1 (no)
AU (1) AU733079B2 (no)
CA (1) CA2271955C (no)
DE (1) DE69736126T2 (no)
DK (1) DK0956360T3 (no)
ES (1) ES2267154T3 (no)
NO (1) NO992369L (no)
PT (1) PT956360E (no)
WO (1) WO1998021354A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
GB2334257B (en) * 1997-12-22 2001-07-04 Oxford Biomedica Ltd Rectroviral vectors
EP1074625A3 (en) 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus
FR2796396A1 (fr) * 1999-07-16 2001-01-19 Merial Sas Gene de calicivirus felin et vaccin recombine les incorporant
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
JP4540033B2 (ja) * 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および/または増強する方法
ATE513913T1 (de) * 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
EP2302059A1 (en) * 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
WO2004110485A1 (en) * 2003-06-13 2004-12-23 Palmowski Michael J Materials and methods for improved vaccination
WO2007136763A2 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Immunological composition
GB2460694A (en) * 2008-06-06 2009-12-09 Secr Defence Attenuated poxviruses
CA2760315C (en) 2009-04-30 2019-05-28 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
HUE065174T2 (hu) 2017-02-12 2024-05-28 Biontech Us Inc HLA-alapú módszerek és készítmények, valamint azok felhasználása
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
EP4158014A2 (en) 2020-05-26 2023-04-05 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5413927A (en) 1991-09-03 1995-05-09 North Carolina State University Feline immunodeficiency virus isolate NCSU1Lb
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
US5833993A (en) 1994-04-29 1998-11-10 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs

Also Published As

Publication number Publication date
JP2000509999A (ja) 2000-08-08
DE69736126D1 (de) 2006-07-27
JP4064466B2 (ja) 2008-03-19
JP2007001990A (ja) 2007-01-11
ES2267154T3 (es) 2007-03-01
DK0956360T3 (da) 2006-10-02
US7255862B1 (en) 2007-08-14
AU733079B2 (en) 2001-05-03
EP0956360B1 (en) 2006-06-14
EP0956360A4 (en) 2003-04-23
ATE330023T1 (de) 2006-07-15
PT956360E (pt) 2006-11-30
DE69736126T2 (de) 2007-01-04
CA2271955A1 (en) 1998-05-22
JP3936303B2 (ja) 2007-06-27
CA2271955C (en) 2010-08-17
JP2003310286A (ja) 2003-11-05
AU5174598A (en) 1998-06-03
EP0956360A1 (en) 1999-11-17
NO992369L (no) 1999-07-06
WO1998021354A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
Barnett et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant
Barouch et al. Reduction of simian-human immunodeficiency virus 89.6 P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
Lema et al. HIV vaccines: A brief overview
Voss et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
US8916174B2 (en) HIV DNA vaccine regulated by a caev-derived promoter
McKay et al. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen
Knudsen et al. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
GARDNER Vaccination against SIV infection and disease
US8765140B2 (en) DNA vaccine compositions with HIV/SIV gene modifications
Musich et al. New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design
Pahar et al. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV
DE60238773D1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
WO2007143606A3 (en) Hiv-1 clade a consensus sequences, antigens, and transgenes
Brown et al. New prospects for a preventive HIV-1 vaccine
Mealey et al. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen
PL365742A1 (en) Vaccination against the feline immunodeficiency virus
Huisman FIV vaccine development: a continuing challenge
Tellier Immunogenicity and protective efficacy evaluation of canarypoxvirus (ALVAC)-based FIV vaccines in cats
Zhou Expression and immunogenicity of DNA vaccines containing the env and gag-pol genes of equine infectious anemia virus